ClinConnect ClinConnect Logo
Search / Trial NCT06714578

Construction of a Risk Screening Tool for New Psychoactive Substance Misuse Among Adolescents and Young Adults

Launched by WEI XIA, PHD · Nov 27, 2024

Trial Information

Current as of August 22, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is focused on creating a tool to help identify young people who might be at risk of misusing new psychoactive substances, which are drugs that can have effects similar to illegal drugs. The study aims to understand how often this kind of drug misuse happens among young adults and adolescents and what factors contribute to it. By doing this, the researchers hope to develop a simple screening tool that can help spot those at risk, allowing for early support and prevention of future addiction issues.

To participate in this study, young people aged 14 to 35 who can read and communicate in Chinese are invited to join. Participants will be asked to complete a questionnaire about their experiences and behaviors related to drug use. This research is important as it seeks to create a reliable way to identify those who may need help, ultimately aiming to reduce the risk of addiction in the future. The study is not yet recruiting participants, so there will be more information available once it begins.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adolescents and young adults who were aged 14-35 years;
  • Adolescents and young adults could read and communicate in Chinese were invited to participate in this study
  • Exclusion Criteria:
  • Adolescents and young adults who were unable to complete the questionnaire due to physical or psychological reasons.

About Wei Xia, Phd

Wei Xia, PhD, is a distinguished clinical trial sponsor with extensive expertise in clinical research and development. With a strong background in biomedical sciences, Dr. Xia has a proven track record of leading innovative studies aimed at advancing therapeutic interventions. His commitment to rigorous scientific methodologies and ethical standards ensures the integrity and reliability of clinical trials. Dr. Xia's collaborative approach fosters partnerships with academic institutions and industry stakeholders, driving forward the translation of research findings into impactful healthcare solutions.

Locations

Guangzhou, Guangdong, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported